These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 9579299)
41. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Kerb R; Aynacioglu AS; Brockmöller J; Schlagenhaufer R; Bauer S; Szekeres T; Hamwi A; Fritzer-Szekeres M; Baumgartner C; Ongen HZ; Güzelbey P; Roots I; Brinkmann U Pharmacogenomics J; 2001; 1(3):204-10. PubMed ID: 11908757 [TBL] [Abstract][Full Text] [Related]
42. Genetic variations of S-mephenytoin 4'-hydroxylase (CYP2C19) in the Chinese population. Xie HG Life Sci; 2000 Feb; 66(14):PL175-81. PubMed ID: 10755474 [TBL] [Abstract][Full Text] [Related]
43. Carbamazepine and oxcarbazepine decrease phenytoin metabolism through inhibition of CYP2C19. Lakehal F; Wurden CJ; Kalhorn TF; Levy RH Epilepsy Res; 2002 Dec; 52(2):79-83. PubMed ID: 12458024 [TBL] [Abstract][Full Text] [Related]
44. [Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy]. Yamamoto Y; Takahashi Y; Nishimura S; Ikumi Y; Mishima N; Kagawa Y Yakugaku Zasshi; 2011; 131(5):809-15. PubMed ID: 21532277 [TBL] [Abstract][Full Text] [Related]
45. Pharmacogenetics of CYP2C subfamily in a Japanese population. Ieiri I; Higuchi S J Toxicol Sci; 1998 Jul; 23 Suppl 2():129-31. PubMed ID: 9760448 [No Abstract] [Full Text] [Related]
46. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Masimirembwa C; Bertilsson L; Johansson I; Hasler JA; Ingelman-Sundberg M Clin Pharmacol Ther; 1995 Jun; 57(6):656-61. PubMed ID: 7781265 [TBL] [Abstract][Full Text] [Related]
47. The effect of CYP2C19 and CYP2D6 genotypes on the metabolism of clomipramine in Japanese psychiatric patients. Yokono A; Morita S; Someya T; Hirokane G; Okawa M; Shimoda K J Clin Psychopharmacol; 2001 Dec; 21(6):549-55. PubMed ID: 11763000 [TBL] [Abstract][Full Text] [Related]
48. High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands. Kaneko A; Lum JK; Yaviong L; Takahashi N; Ishizaki T; Bertilsson L; Kobayakawa T; Björkman A Pharmacogenetics; 1999 Oct; 9(5):581-90. PubMed ID: 10591538 [TBL] [Abstract][Full Text] [Related]
49. Population estimation regarding the effects of cytochrome P450 2C19 and 3A5 polymorphisms on zonisamide clearance. Okada Y; Seo T; Ishitsu T; Wanibuchi A; Hashimoto N; Higa Y; Nakagawa K Ther Drug Monit; 2008 Aug; 30(4):540-3. PubMed ID: 18641551 [TBL] [Abstract][Full Text] [Related]
50. Genotype analysis of the CYP2C19 gene in the Japanese population. Tsuneoka Y; Fukushima K; Matsuo Y; Ichikawa Y; Watanabe Y Life Sci; 1996; 59(20):1711-5. PubMed ID: 8890945 [TBL] [Abstract][Full Text] [Related]
51. CYP2C19 genotype does not represent a genetic predisposition in idiopathic systemic lupus erythematosus. Kortunay S; Bozkurt A; Bathum L; Basci NE; Calgüneri M; Brøsen K; Kayaalp SO Ann Rheum Dis; 1999 Mar; 58(3):182-5. PubMed ID: 10364917 [TBL] [Abstract][Full Text] [Related]
52. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects. Ieiri I; Kubota T; Urae A; Kimura M; Wada Y; Mamiya K; Yoshioka S; Irie S; Amamoto T; Nakamura K; Nakano S; Higuchi S Clin Pharmacol Ther; 1996 Jun; 59(6):647-53. PubMed ID: 8681489 [TBL] [Abstract][Full Text] [Related]
53. CYP2C polymorphisms, phenytoin metabolism and gingival overgrowth in epileptic subjects. Soga Y; Nishimura F; Ohtsuka Y; Araki H; Iwamoto Y; Naruishi H; Shiomi N; Kobayashi Y; Takashiba S; Shimizu K; Gomita Y; Oka E Life Sci; 2004 Jan; 74(7):827-34. PubMed ID: 14659971 [TBL] [Abstract][Full Text] [Related]
54. Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes. Hall SD; Guengerich FP; Branch RA; Wilkinson GR J Pharmacol Exp Ther; 1987 Jan; 240(1):216-22. PubMed ID: 2879902 [TBL] [Abstract][Full Text] [Related]
55. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. Ibeanu GC; Blaisdell J; Ferguson RJ; Ghanayem BI; Brosen K; Benhamou S; Bouchardy C; Wilkinson GR; Dayer P; Goldstein JA J Pharmacol Exp Ther; 1999 Aug; 290(2):635-40. PubMed ID: 10411572 [TBL] [Abstract][Full Text] [Related]
56. Phenocopies of poor metabolizers of omeprazole caused by liver disease and drug treatment. Rost KL; Brockmöller J; Esdorn F; Roots I J Hepatol; 1995 Sep; 23(3):268-77. PubMed ID: 8550990 [TBL] [Abstract][Full Text] [Related]
57. Effect of mild therapeutic hypothermia on phenytoin pharmacokinetics. Iida Y; Nishi S; Asada A Ther Drug Monit; 2001 Jun; 23(3):192-7. PubMed ID: 11360024 [TBL] [Abstract][Full Text] [Related]
58. Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations. Kaneko A; Bergqvist Y; Taleo G; Kobayakawa T; Ishizaki T; Björkman A Pharmacogenetics; 1999 Jun; 9(3):317-26. PubMed ID: 10471063 [TBL] [Abstract][Full Text] [Related]
59. A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Kosaki K; Tamura K; Sato R; Samejima H; Tanigawara Y; Takahashi T Brain Dev; 2004 Dec; 26(8):530-4. PubMed ID: 15533655 [TBL] [Abstract][Full Text] [Related]
60. Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevitY. Role of CYP2D6 and CYP2C19 in longevity. Bathum L; Andersen-Ranberg K; Boldsen J; Brøsen K; Jeune B Eur J Clin Pharmacol; 1998 Jul; 54(5):427-30. PubMed ID: 9754988 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]